Did you mean: KABoki

COVID-19 infection among autoimmune rheumatic disease patients: data from an observational study and literature review

AD Bakasis, CP Mavragani, KA Boki, AG Tzioufas… - Journal of …, 2021 - Elsevier
The impact of SARS-CoV-2 infection in patients with autoimmune/auto-inflammatory rheumatic
diseases (AARD) under immunomodulatory treatment has been a focus of interest during …

[HTML][HTML] Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

JPA Ioannidis, KA Boki, ME Katsorida, AA Drosos… - Kidney international, 2000 - Elsevier
Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide.
Background Long-term intravenous cyclophosphamide (IVC) in combination with …

Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis

…, M Kokosi, A Tzioufas, SP Toya, KA Boki… - European …, 2010 - Eur Respiratory Soc
We sought to determine the type of pulmonary involvement in microscopic polyangiitis (MPA),
primarily focusing on pulmonary fibrosis (PF), its prevalence, temporal relationship with …

Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis

JN Boletis, JPA Ioannidis, KA Boki, HM Moutsopoulos - The Lancet, 1999 - thelancet.com
Among 14 randomised patients with proliferative lupus nephritis, monthly intravenous
immunoglobulin maintained remission over 18 months, similar to standard intravenous …

Risk factors for central nervous system involvement in systemic lupus erythematosus

FB Karassa, JPA Ioannidis, G Touloumi, KA Boki… - Qjm, 2000 - academic.oup.com
We investigated risk factors for central nervous system (CNS) involvement in systemic lupus
erythematosus (SLE), in 32 such patients individually matched 1 : 3 to 96 control SLE …

Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of …

I Flouri, TE Markatseli, PV Voulgari, KA Boki… - Seminars in arthritis and …, 2014 - Elsevier
Boki MD c , Ioannis Papadopoulos MD d , Loukas Settas MD e , Dimitrios Zisopoulos MD
e f , Fotini N. Skopouli MD g , Alexios Iliopoulos MD h , George K. Bertsias MD a , Pierre …

Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus

FB Karassa, JPA Ioannidis, KA Boki, G Touloumi… - The American journal of …, 2000 - Elsevier
PURPOSE: We sought to identify the predictors of clinical outcome and of the evolution of
cerebral abnormalities in patients with neuropsychiatric systemic lupus erythematosus (SLE). …

The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients …

…, NG Tzortzakis, E Panou-Pomonis, KA Boki… - Annals of the …, 2000 - ard.bmj.com
OBJECTIVES To develop an enzyme linked immunosorbent assay (ELISA) using as substrate
a synthetic 22-aminoacid peptide, corresponding to the ribosomal P0, P1 and P2 common …

[PDF][PDF] Is the heart affected in primary Sjogren's syndrome? An echocardiographic study

VA Vassiliou, I Moyssakis, KA Boki… - Clinical and …, 2008 - clinexprheumatol.org
Objective. To evaluate whether patients with primary Sjögren’s syndrome with-’out overt
cardiac disease have echocardiographic abnormalities and their relation with clinical and …

Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome

MG Tektonidou, JPA Ioannidis, KA Boki… - Qjm, 2000 - academic.oup.com
We assessed whether initial clinical presentations suggestive of antiphospholipid syndrome
(APS) predicted the subsequent rate and type of serious clinical outcomes. Eighty‐two …
Did you mean to search for: KABoki